Drug Profile
JNJ 64140284
Alternative Names: AMPARγ8; JNJ-64140284Latest Information Update: 28 Oct 2022
Price :
$50
*
At a glance
- Originator Janssen Research & Development
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Oct 2022 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in Belgium
- 01 Oct 2020 JNJ 64140284 is still in phase I trial (In volunteers) in Belgium (NCT04566926)
- 28 Sep 2020 Janssen Pharmaceutica plans the AMPAR phase I trial (In volunteers) in Belgium (PO) (NCT04566926)